MCID: SPL004
MIFTS: 51

Splenic Marginal Zone Lymphoma

Categories: Blood diseases, Rare diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Splenic Marginal Zone Lymphoma

MalaCards integrated aliases for Splenic Marginal Zone Lymphoma:

Name: Splenic Marginal Zone Lymphoma 38 12 59 15
Splenic Marginal Zone B-Cell Lymphoma 73
Smzl 59

Characteristics:

Orphanet epidemiological data:

59
splenic marginal zone lymphoma
Age of onset: Adult;

Classifications:



External Ids:

Disease Ontology 12 DOID:0050750
Orphanet 59 ORPHA86854
UMLS via Orphanet 74 C0349632
ICD10 via Orphanet 34 C83.0
UMLS 73 C0349632

Summaries for Splenic Marginal Zone Lymphoma

Disease Ontology : 12 A marginal zone B-cell lymphocyte located in the spleen comprised of B-cells in place of white pulp.

MalaCards based summary : Splenic Marginal Zone Lymphoma, also known as splenic marginal zone b-cell lymphoma, is related to reticulosarcoma and diffuse large b-cell lymphoma. An important gene associated with Splenic Marginal Zone Lymphoma is NOTCH2 (Notch 2), and among its related pathways/superpathways are NF-kappaB Signaling and Transcriptional misregulation in cancer. The drugs Cyclophosphamide and Lenograstim have been mentioned in the context of this disorder. Affiliated tissues include the spleen comprised of b-cells in place of white pulp, bone and b cells, and related phenotypes are hematopoietic system and immune system

Wikipedia : 76 Splenic marginal zone lymphoma (SMZL) is a type of cancer (specifically a lymphoma) made up of B-cells... more...

Related Diseases for Splenic Marginal Zone Lymphoma

Diseases related to Splenic Marginal Zone Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 80)
# Related Disease Score Top Affiliating Genes
1 reticulosarcoma 30.3 BCL6 PAX5
2 diffuse large b-cell lymphoma 30.1 BCL6 CD5 MALT1
3 mantle cell lymphoma 30.1 BCL6 CD5 MALT1 PAX5
4 macroglobulinemia 30.1 ITGAE PAX5
5 burkitt lymphoma 30.0 BCL6 BIRC3 PAX5
6 b-cell lymphomas 29.8 BCL6 BIRC3 CD5 MALT1 PAX5
7 lymphoma, mucosa-associated lymphoid type 29.6 BCL6 BIRC3 CD5 MALT1
8 lymphoma, non-hodgkin, familial 29.2 BCL6 BIRC3 CD5 MALT1 PAX5
9 lymphoma 11.1
10 nodular lymphocyte predominant hodgkin lymphoma 10.7 BCL6 PAX5
11 nodal marginal zone b-cell lymphoma 10.7 BCL6 MALT1
12 intraocular lymphoma 10.6 BCL6 PAX5
13 primary central nervous system lymphoma 10.6 BCL6 PAX5
14 bladder lymphoma 10.6 CD5 PAX5
15 nodal marginal zone lymphoma 10.6 CD5 NOTCH2
16 breast lymphoma 10.5 BCL6 CD5
17 intravascular large b-cell lymphoma 10.5 BCL6 CD5
18 cll/sll 10.5 CD5 PAX5
19 orofaciodigital syndrome viii 10.5 BIRC3 MALT1
20 multicentric castleman disease 10.5 BCL6 PAX5
21 lymphoplasmacytic lymphoma 10.5 CD5 PAX5
22 colon lymphoma 10.5 BCL6 CD5
23 hepatitis 10.4
24 mediastinal malignant lymphoma 10.4 BCL6 PAX5
25 epidural neoplasm 10.4 BCL6 CD5
26 hepatitis c 10.4
27 hepatitis c virus 10.3
28 lymphatic system cancer 10.3 BCL6 CD5
29 hemolytic anemia 10.3
30 composite lymphoma 10.3 BCL6 CD5 PAX5
31 anemia, autoimmune hemolytic 10.2
32 lymphoma, hodgkin, classic 10.2
33 prostate lymphoma 10.2 BIRC3 CD5 MALT1
34 hepatitis b 10.2
35 central nervous system lymphoma 10.1 BCL6 MALT1
36 glomerulonephritis 10.1
37 thrombosis 10.1
38 hairy cell leukemia 10.1
39 cerebritis 10.1
40 paraplegia 10.1
41 hepatocellular carcinoma 9.9
42 temporal arteritis 9.9
43 myelofibrosis 9.9
44 myeloma, multiple 9.9
45 polycythemia vera 9.9
46 membranous nephropathy 9.9
47 autoimmune lymphoproliferative syndrome, type v 9.9
48 leukemia 9.9
49 neutropenia 9.9
50 systemic mastocytosis 9.9

Graphical network of the top 20 diseases related to Splenic Marginal Zone Lymphoma:



Diseases related to Splenic Marginal Zone Lymphoma

Symptoms & Phenotypes for Splenic Marginal Zone Lymphoma

MGI Mouse Phenotypes related to Splenic Marginal Zone Lymphoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.02 NOTCH2 BCL6 PAX5 BIRC3 TRAF3 CD5
2 immune system MP:0005387 9.96 NOTCH2 BCL6 PAX5 BIRC3 TRAF3 CD5
3 mortality/aging MP:0010768 9.85 NOTCH2 BCL6 PAX5 BIRC3 TRAF3 TRRAP
4 no phenotypic analysis MP:0003012 9.43 NOTCH2 BCL6 TRAF3 CD5 FAT4 KLF2
5 normal MP:0002873 9.1 NOTCH2 BCL6 PAX5 BIRC3 CD5 KLF2

Drugs & Therapeutics for Splenic Marginal Zone Lymphoma

Drugs for Splenic Marginal Zone Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 429)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
2
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
3
Thiotepa Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 52-24-4 5453
4 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
5 Antilymphocyte Serum Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
6 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
7 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
8 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
9
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
10
Fludarabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 21679-14-1, 75607-67-9 30751
11
Pixantrone Approved, Investigational Phase 3 144510-96-3
12
rituximab Approved Phase 3,Phase 1,Phase 2,Not Applicable 174722-31-7 10201696
13
Vidarabine Approved, Investigational Phase 3,Phase 1,Phase 2,Not Applicable 24356-66-9 32326 21704
14
Iron Approved Phase 3,Phase 2,Phase 1,Not Applicable 7439-89-6 23925
15
Amoxicillin Approved, Vet_approved Phase 3,Not Applicable 26787-78-0 33613
16
Ciprofloxacin Approved, Investigational Phase 3,Not Applicable 85721-33-1 2764
17
Chlorambucil Approved Phase 3 305-03-3 2708
18
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Not Applicable 50-02-2 5743
19
Idarubicin Approved Phase 3 58957-92-9 42890
20
Cefepime Approved, Investigational Phase 3,Phase 1 88040-23-7 5479537
21
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
22
Ofloxacin Approved Phase 3 82419-36-1 4583
23
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 55-98-1 2478
24
Melphalan Approved Phase 3,Phase 2,Phase 1,Not Applicable 148-82-3 4053 460612
25
Doxorubicin Approved, Investigational Phase 3,Phase 1,Phase 2,Not Applicable 23214-92-8 31703
26
Prednisone Approved, Vet_approved Phase 3,Phase 2,Phase 1 53-03-2 5865
27
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
28
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
29
Carboplatin Approved Phase 2, Phase 3,Phase 1,Not Applicable 41575-94-4 10339178 498142 38904
30
Etoposide Approved Phase 2, Phase 3,Phase 1,Early Phase 1,Not Applicable 33419-42-0 36462
31
Mycophenolate mofetil Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 128794-94-5 5281078
32
Mycophenolic acid Approved Phase 3,Phase 2,Phase 1,Not Applicable 24280-93-1 446541
33
Ephedrine Approved Phase 3 299-42-3 9294
34
Pseudoephedrine Approved Phase 3 90-82-4 7028
35
Darbepoetin alfa Approved, Investigational Phase 3,Phase 2 11096-26-7, 209810-58-2
36
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
37
Piperacillin Approved Phase 3 66258-76-2 43672
38
Tazobactam Approved Phase 3 89786-04-9 123630
39
Vancomycin Approved Phase 3 1404-90-6 441141 14969
40
Dalteparin Approved Phase 3 9005-49-6
41
Heparin Approved, Investigational Phase 3,Not Applicable 9005-49-6 772 46507594
42
Captopril Approved Phase 3 62571-86-2 44093
43
Palivizumab Approved, Investigational Phase 3 188039-54-5
44
Ribavirin Approved Phase 3 36791-04-5 37542
45
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
46
Itraconazole Approved, Investigational Phase 3,Not Applicable 84625-61-6 55283
47
Ondansetron Approved Phase 3,Phase 2,Phase 1,Not Applicable 99614-02-5 4595
48
Aldesleukin Approved Phase 3,Phase 2,Phase 1 85898-30-2, 110942-02-4
49
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
50
Caspofungin Approved Phase 3,Phase 2 179463-17-3, 162808-62-0 468682 2826718

Interventional clinical trials:

(show top 50) (show all 490)
# Name Status NCT ID Phase Drugs
1 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
2 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
3 Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma Unknown status NCT00551239 Phase 3 fludarabine phosphate;pixantrone dimaleate
4 Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With Cancer Unknown status NCT00482716 Phase 3
5 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
6 Combination Chemotherapy With or Without Interferon Alfa in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma Unknown status NCT00003639 Phase 3 chlorambucil;dexamethasone;idarubicin
7 Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma Unknown status NCT00003924 Phase 3
8 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
9 Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma Unknown status NCT00003338 Phase 2, Phase 3
10 Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003337 Phase 3
11 Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome Unknown status NCT00002989 Phase 3 busulfan;cyclophosphamide;idarubicin;melphalan
12 Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
13 Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia Completed NCT00566332 Phase 3 Chlorambucil;Fludarabine
14 Chlorambucil or Fludarabine as First-Line Therapy in Treating Patients With Previously Untreated Waldenström Macroglobulinemia, Splenic Lymphoma, or Lymphoplasmacytic Lymphoma Completed NCT00608374 Phase 3 chlorambucil;fludarabine phosphate
15 Safety and Efficacy Study of BCD-020 in Therapy of Indolent Non-Hodgkin's Lymphoma Completed NCT01701232 Phase 3
16 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
17 Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder Completed NCT00755040 Phase 3 cyclosporine ophthalmic emulsion
18 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
19 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
20 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
21 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
22 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
23 Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases Completed NCT00438958 Phase 3
24 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
25 Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer Completed NCT00265837 Phase 3
26 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
27 Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
28 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
29 Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma Completed NCT00004112 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
30 Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
31 Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation Completed NCT00014391 Phase 3 ribavirin
32 Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation Completed NCT00003883 Phase 3 fluconazole;itraconazole
33 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
34 Graft-Versus-Host Disease in Treating Patients With Recurrent or Refractory Lymphoma or Hodgkin's Disease Completed NCT00003414 Phase 3 busulfan;cyclophosphamide;cyclosporine
35 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
36 Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy Completed NCT00003341 Phase 3
37 Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer Completed NCT00053053 Phase 3
38 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
39 Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma Completed NCT00005590 Phase 3 levofloxacin
40 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
41 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
42 Rituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma Active, not recruiting NCT00075946 Phase 3
43 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
44 Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
45 Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD) Terminated NCT00089141 Phase 3 mycophenolate mofetil;placebo
46 Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation Terminated NCT00003056 Phase 3 cyclosporine;cyclosporine and methotrexate
47 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2 brentuximab vedotin
48 Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders Unknown status NCT00740467 Phase 2 busulfan;cyclophosphamide;cyclosporine;fludarabine phosphate;mycophenolate mofetil
49 Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma Unknown status NCT00397800 Phase 1, Phase 2 cyclophosphamide;fludarabine phosphate
50 Arsenic Trioxide in Treating Patients With Recurrent or Refractory Acute Leukemia, Chronic Myeloide Leukemia, Myelodysplasia, Lymphoma, or Myeloma Unknown status NCT00003885 Phase 2 arsenic trioxide

Search NIH Clinical Center for Splenic Marginal Zone Lymphoma

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Splenic Marginal Zone Lymphoma cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Splenic Marginal Zone Lymphoma:
Hematopoietic stem cells for treatment of hematologic malignancies
Embryonic/Adult Cultured Cells Related to Splenic Marginal Zone Lymphoma:
Bone marrow-derived hematopoietic stem cells

Genetic Tests for Splenic Marginal Zone Lymphoma

Anatomical Context for Splenic Marginal Zone Lymphoma

The Foundational Model of Anatomy Ontology organs/tissues related to Splenic Marginal Zone Lymphoma:

19
The Spleen Comprised Of B-Cells In Place Of White Pulp

MalaCards organs/tissues related to Splenic Marginal Zone Lymphoma:

41
Bone, B Cells, Bone Marrow, Spleen, T Cells, Kidney, Liver

Publications for Splenic Marginal Zone Lymphoma

Articles related to Splenic Marginal Zone Lymphoma:

(show top 50) (show all 239)
# Title Authors Year
1
Should rituximab replace splenectomy in the management of splenic marginal zone lymphoma? ( 29452668 )
2018
2
Splenic marginal zone lymphoma relapsing as miliary lung mottling: an unusual presentation. ( 29963513 )
2018
3
Remission of Cutaneous Involvement in Splenic Marginal Zone Lymphoma after Splenectomy. ( 29856467 )
2018
4
Splenic marginal zone lymphoma with a de novo t(8;14)(q24;q32) and a prolymphocytoid evolution responsive to rituximab-bendamustine. ( 29728736 )
2018
5
Rituximab monotherapy in splenic marginal zone lymphoma: prolonged responses and potential benefit from maintenance. ( 29914978 )
2018
6
18F-FDG PET/CT in splenic marginal zone lymphoma. ( 29500652 )
2018
7
Idelalisib and Rituximab in 17p Deletion-Positive Splenic Marginal Zone Lymphoma. ( 29523661 )
2018
8
Bone marrow-derived mesenchymal stem/stromal cells from patients with splenic marginal zone lymphoma are intrinsically impaired and influence the malignant B-cells. ( 29966468 )
2018
9
Surgical management of splenic marginal zone lymphoma. ( 29043543 )
2017
10
Important Diagnostic Clues for Diagnosing Splenic Marginal Zone Lymphoma in Absence of Splenic Histology. ( 28892912 )
2017
11
Differential gene expression profiling linked to tumor progression of splenic marginal zone lymphoma. ( 28887496 )
2017
12
Improved biological insight and influence on management in indolent lymphoma. Talk 3: update on nodal and splenic marginal zone lymphoma. ( 29222281 )
2017
13
Still a role for surgery as first-line therapy of splenic marginal zone lymphoma? Results of a prospective observational study. ( 28366762 )
2017
14
Prevalence of hepatitis B and hepatitis C viral infections in various subtypes of B-cell non-Hodgkin lymphoma: confirmation of the association with splenic marginal zone lymphoma. ( 28362442 )
2017
15
BRAF (V600E) expression in histiocytic sarcoma associated with splenic marginal zone lymphoma: a case report. ( 28376906 )
2017
16
Distinct clinical characteristics draw a new prognostic model for splenic marginal zone lymphoma in HBV high prevalent region. ( 29228725 )
2017
17
Treatment of splenic marginal zone lymphoma. ( 28288709 )
2017
18
Indolent B-Cell Lymphoid Malignancy in the Spleen of a Man WhoA Handled Benzene: Splenic Marginal Zone Lymphoma. ( 28951809 )
2017
19
High-Grade Transformation in a Splenic Marginal Zone Lymphoma with a Cerebral Manifestation. ( 28566677 )
2017
20
Splenic Marginal Zone Lymphoma with Acquired von Willebrand Syndrome Diagnosed via Splenic Bleeding. ( 28250305 )
2017
21
Splenic marginal zone lymphoma. ( 28288718 )
2017
22
Clinical and diagnostic relevance of NOTCH2-and KLF2-mutations in splenic marginal zone lymphoma. ( 28522570 )
2017
23
Splenic marginal zone lymphoma: a literature review of diagnostic and therapeutic challenges. ( 28577652 )
2017
24
Splenic marginal zone lymphoma uncovered after a 10-year follow up as anemia of unknown cause. ( 28190866 )
2017
25
Splenic marginal zone lymphoma: excellent outcomes in 64 patients treated in the rituximab era. ( 28105889 )
2017
26
Splenic marginal zone lymphoma complicated by cold agglutinin disease. ( 28321090 )
2017
27
An Immunogenetic Signature of Ongoing Antigen Interactions in Splenic Marginal Zone Lymphoma Expressing IGHV1-2*04 Receptors. ( 26647217 )
2016
28
No evidence of splenic disease in patients with splenic marginal zone lymphoma undergoing splenectomy for autoimmune hemolytic anemia after monotherapy with rituximab. ( 27082039 )
2016
29
High prevalence of splenic marginal zone lymphoma among patients with acquired C1 inhibtor deficiency. ( 26728240 )
2016
30
Synchronous rectal adenocarcinoma and splenic marginal zone lymphoma. ( 26966416 )
2016
31
Murine Models of Splenic Marginal Zone Lymphoma: A Role for Cav1? ( 28018857 )
2016
32
How to treat splenic marginal zone lymphoma (SMZL) in patients unfit for surgery or more aggressive therapies: experience in 30 cases. ( 27454143 )
2016
33
NF-I_B deregulation in splenic marginal zone lymphoma. ( 27503810 )
2016
34
Paraneoplastic Syndrome in Splenic Marginal Zone Lymphoma: A Rare Phenomenon of Paraplegia as an Atypical Presenting Manifestation. ( 27293921 )
2016
35
Splenic marginal zone lymphoma: Prognostic factors, role of watch and wait policy, and other therapeutic approaches in the rituximab era. ( 27030961 )
2016
36
Splenic marginal zone lymphoma: An indolent malignancy leading to the development of neurolymphomatosis. ( 27625159 )
2016
37
Rituximab in a patient with splenic marginal zone lymphoma and acquired angioedema. ( 27017557 )
2016
38
Primary splenic marginal zone lymphoma: A case report. ( 27772948 )
2016
39
Splenic marginal zone lymphoma: from genetics to management. ( 26989207 )
2016
40
High prevalence of viral hepatitis in a series of splenic marginal zone lymphomas from Romania. ( 27834940 )
2016
41
Whole exome sequencing of microdissected splenic marginal zone lymphoma: a study to discover novel tumor-specific mutations. ( 26498442 )
2015
42
DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features. ( 25612624 )
2015
43
Polymyalgia rheumatica in a patient with splenic marginal zone lymphoma - a case report. ( 25815618 )
2015
44
Remission of splenic marginal zone lymphoma in a patient treated for hepatitis B: a case of HBV-associated lymphoma. ( 25977147 )
2015
45
Toll-like receptor stimulation in splenic marginal zone lymphoma can modulate cell signaling, activation and proliferation. ( 26294727 )
2015
46
Success of interferon I+ therapy in a patient with hepatitis C virus-negative splenic marginal zone lymphoma associated with polycythemia vera. ( 25641434 )
2015
47
Outcomes in splenic marginal zone lymphoma: analysis of 107 patients treated in British Columbia. ( 25854936 )
2015
48
R-COMP as a first-line treatment for Splenic Marginal Zone Lymphoma. A Fondazione Italiana Linfomi phase II study. ( 25791121 )
2015
49
Successful Treatment of Leukemic Mature B-Cell Lymphoid Neoplasm with Similar Features to Splenic Marginal Zone Lymphoma Possessing Aberrant Myeloid Markers. ( 26558117 )
2015
50
Tissue proteomics of splenic marginal zone lymphoma. ( 25873066 )
2015

Variations for Splenic Marginal Zone Lymphoma

Cosmic variations for Splenic Marginal Zone Lymphoma:

9
(show top 50) (show all 53)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM4944029 TRAF3 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.193C>T p.Q65* 14:102870394-102870394 6
2 COSM10660 TP53 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.818G>A p.R273H 17:7673802-7673802 6
3 COSM11073 TP53 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.1024C>T p.R342* 17:7670685-7670685 6
4 COSM43842 TP53 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.770T>C p.L257P 17:7674193-7674193 6
5 COSM44216 TP53 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.487T>G p.Y163D 17:7675125-7675125 6
6 COSM11374 TP53 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.752T>A p.I251N 17:7674211-7674211 6
7 COSM10726 TP53 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.856G>A p.E286K 17:7673764-7673764 6
8 COSM43909 TP53 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.817C>A p.R273S 17:7673803-7673803 6
9 COSM43949 TP53 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.401T>G p.F134C 17:7675211-7675211 6
10 COSM10742 TP53 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.578A>G p.H193R 17:7674953-7674953 6
11 COSM10701 TP53 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.824G>T p.C275F 17:7673796-7673796 6
12 COSM43606 TP53 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.734G>A p.G245D 17:7674229-7674229 6
13 COSM44215 TP53 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.533A>C p.H178P 17:7675079-7675079 6
14 COSM133689 TNFAIP3 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.2209C>T p.Q737* 6:137881155-137881155 6
15 COSM133688 TNFAIP3 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.553G>T p.G185* 6:137875754-137875754 6
16 COSM4944038 TBL1XR1 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.1058A>G p.N353S 3:177038162-177038162 6
17 COSM4944027 SPEN haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.5428C>G p.P1810A 1:15931668-15931668 6
18 COSM3802617 SPEN haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.2170C>T p.R724* 1:15928410-15928410 6
19 COSM1639597 SPEN haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.3793C>T p.R1265* 1:15930033-15930033 6
20 COSM4944040 SIN3A haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.430T>C p.Y144H 15:75414248-75414248 6
21 COSM4944041 SIN3A haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.1232C>T p.P411L 15:75409921-75409921 6
22 COSM674043 NOTCH2 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.7078C>T p.Q2360* 1:119915644-119915644 6
23 COSM329077 NOTCH2 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.6973C>T p.Q2325* 1:119915749-119915749 6
24 COSM329072 NOTCH2 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.6853C>T p.Q2285* 1:119915869-119915869 6
25 COSM36210 NOTCH2 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.7198C>T p.R2400* 1:119915524-119915524 6
26 COSM36073 NOTCH2 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.7021C>T p.Q2341* 1:119915701-119915701 6
27 COSM674042 NOTCH2 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.7090C>T p.Q2364* 1:119915632-119915632 6
28 COSM329075 NOTCH2 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.7072A>G p.M2358V 1:119915650-119915650 6
29 COSM329069 NOTCH2 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.6304A>T p.K2102* 1:119916418-119916418 6
30 COSM957497 NOTCH2 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.7030G>T p.E2344* 1:119915692-119915692 6
31 COSM1168004 NOTCH2 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.7231G>T p.E2411* 1:119915491-119915491 6
32 COSM329079 NOTCH2 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.6868G>A p.E2290K 1:119915854-119915854 6
33 COSM876755 NOTCH2 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.7163C>G p.S2388* 1:119915559-119915559 6
34 COSM85940 MYD88 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.794T>C p.L265P 3:38141150-38141150 6
35 COSM4944023 IKBKB haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.511A>G p.K171E 8:42306376-42306376 6
36 COSM4944024 IKBKB haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.512A>C p.K171T 8:42306377-42306377 6
37 COSM4944042 FAT4 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.739C>A p.P247T 4:125317150-125317150 6
38 COSM5981986 CXCR4 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.1025C>G p.S342* 2:136114915-136114915 6
39 COSM30440 CARD11 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.572A>G p.N191S 7:2944324-2944324 6
40 COSM133704 CARD11 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.770T>C p.I257T 7:2939843-2939843 6
41 COSM41660 CARD11 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.1070A>T p.D357V 7:2937980-2937980 6
42 COSM85864 CARD11 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.1202A>T p.D401V 7:2937176-2937176 6
43 COSM674177 CARD11 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.583G>C p.V195L 7:2944313-2944313 6
44 COSM133703 CARD11 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.746A>C p.Q249P 7:2939867-2939867 6
45 COSM220934 CARD11 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.1201G>A p.D401N 7:2937177-2937177 6
46 COSM674179 CARD11 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.1082A>G p.Y361C 7:2937968-2937968 6
47 COSM476 BRAF haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.1799T>A p.V600E 7:140753336-140753336 6
48 COSM1735759 BIRC3 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.1636G>T p.E546* 11:102336923-102336923 6
49 COSM4944028 BIRC3 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.1716T>A p.C572* 11:102337003-102337003 6
50 COSM1350362 BIRC3 haematopoietic and lymphoid tissue,spleen,lymphoid neoplasm,marginal zone lymphoma c.1690G>T p.E564* 11:102336977-102336977 6

Copy number variations for Splenic Marginal Zone Lymphoma from CNVD:

7 (show top 50) (show all 56)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 31168 1 25800000 154800000 Duplication Splenic marginal zone lymphoma
2 38774 10 104900000 119100000 Deletion Splenic marginal zone lymphoma
3 56497 11 59700000 61400000 Duplication Splenic marginal zone lymphoma
4 69123 12 53100000 55200000 Gain GLI1 Splenic marginal zone lymphoma
5 78495 13 52200000 109100000 Gain Splenic marginal zone lymphoma
6 86225 14 55800000 78400000 Loss Splenic marginal zone lymphoma
7 91971 15 37900000 47600000 Deletion Splenic marginal zone lymphoma
8 97450 16 10300000 16700000 Gain Splenic marginal zone lymphoma
9 106744 17 1 11200000 Deletion Splenic marginal zone lymphoma
10 106745 17 1 11200000 Deletion Splenic marginal zone lymphoma
11 108750 17 22200000 78774742 Duplication Splenic marginal zone lymphoma
12 119209 18 1 76117153 Duplication Splenic marginal zone lymphoma
13 120285 18 23300000 31000000 Deletion Splenic marginal zone lymphoma
14 134527 2 102400000 159600000 Deletion Splenic marginal zone lymphoma
15 155734 20 57900000 62435964 Duplication Splenic marginal zone lymphoma
16 160287 22 11800000 49691432 Duplication Splenic marginal zone lymphoma
17 166594 3 104400000 107800000 Deletion Splenic marginal zone lymphoma
18 173065 3 189400000 193800000 Duplication Splenic marginal zone lymphoma
19 177287 3 5500000 8700000 Deletion Splenic marginal zone lymphoma
20 178512 3 74200000 83700000 Duplication Splenic marginal zone lymphoma
21 181981 4 131300000 151000000 Deletion Splenic marginal zone lymphoma
22 190152 4 84000000 161500000 Deletion Splenic marginal zone lymphoma
23 190418 4 88200000 94000000 Duplication Splenic marginal zone lymphoma
24 201328 5 68400000 73300000 Duplication Splenic marginal zone lymphoma
25 207408 6 155600000 160900000 Duplication Splenic marginal zone lymphoma
26 209385 6 26100000 45200000 Duplication Splenic marginal zone lymphoma
27 212692 6 40600000 45200000 Duplication Splenic marginal zone lymphoma
28 217433 7 101175494 101390682 Deletion CUX1 Splenic marginal zone lymphoma
29 217434 12 109956211 110272739 Deletion CUX2 Splenic marginal zone lymphoma
30 217435 7 101175494 101390682 Deletion MUC12 Splenic marginal zone lymphoma
31 217436 7 101175494 101390682 Deletion MUC3 Splenic marginal zone lymphoma
32 218058 7 107200000 147500000 Deletion Splenic marginal zone lymphoma
33 219020 7 120900000 123600000 Loss POT1 Splenic marginal zone lymphoma
34 219788 7 130078078 130270796 Deletion AGK Splenic marginal zone lymphoma
35 219789 7 130078078 130270796 Deletion BPGM Splenic marginal zone lymphoma
36 219790 7 130078078 130270796 Deletion CALD1 Splenic marginal zone lymphoma
37 219791 7 130078078 130270796 Deletion CNTNAP2 Splenic marginal zone lymphoma
38 219792 7 130078078 130270796 Deletion FOXP2 Splenic marginal zone lymphoma
39 219793 7 130078078 130270796 Deletion GRM8 Splenic marginal zone lymphoma
40 219794 7 130078078 130270796 Deletion IMMP2L Splenic marginal zone lymphoma
41 219795 7 130078078 130270796 Deletion KEL Splenic marginal zone lymphoma
42 219796 7 130078078 130270796 Deletion MET Splenic marginal zone lymphoma
43 219797 7 130078078 130270796 Deletion MLKN1 Splenic marginal zone lymphoma
44 219798 7 130078078 130270796 Deletion PTN Splenic marginal zone lymphoma
45 219799 7 130078078 130270796 Deletion PTPRZ1 Splenic marginal zone lymphoma
46 219800 7 130078078 130270796 Deletion ST7 Splenic marginal zone lymphoma
47 219801 7 130078078 130270796 Deletion SVOPL Splenic marginal zone lymphoma
48 219802 7 130078078 130270796 Deletion TES Splenic marginal zone lymphoma
49 219803 7 130078078 130270796 Deletion THAP5 Splenic marginal zone lymphoma
50 219804 7 130078078 130270796 Deletion TPK1 Splenic marginal zone lymphoma

Expression for Splenic Marginal Zone Lymphoma

Search GEO for disease gene expression data for Splenic Marginal Zone Lymphoma.

Pathways for Splenic Marginal Zone Lymphoma

Pathways related to Splenic Marginal Zone Lymphoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.97 BCL6 MALT1 PAX5 TRAF3
2 11.81 BCL6 BIRC3 PAX5
3 11.7 BIRC3 MALT1 TRAF3
4 11.11 BIRC3 MALT1 TRAF3
5 10.8 BIRC3 TRAF3
6 10.52 BCL6 CD5 PAX5

GO Terms for Splenic Marginal Zone Lymphoma

Biological processes related to Splenic Marginal Zone Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein ubiquitination GO:0016567 9.62 BIRC3 FBXO11 MALT1 TRAF3
2 negative regulation of apoptotic process GO:0043066 9.56 BCL6 BIRC3 MALT1 NOTCH2
3 hippo signaling GO:0035329 9.16 AMOTL1 FAT4
4 TRIF-dependent toll-like receptor signaling pathway GO:0035666 8.96 BIRC3 TRAF3
5 regulation of apoptotic process GO:0042981 8.92 BCL6 BIRC3 MALT1 TRAF3

Molecular functions related to Splenic Marginal Zone Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.73 AMOTL1 BCL6 BIRC3 CD5 FAT4 FBXO11
2 ubiquitin-protein transferase activity GO:0004842 8.92 BIRC3 FBXO11 MALT1 TRAF3

Sources for Splenic Marginal Zone Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....